Navigation Links
IntegriChain Appoints John Bailye to Its Board of Directors
Date:6/2/2008

PRINCETON, N.J., June 2 /PRNewswire/ -- IntegriChain, Inc. today announced the appointment of industry veteran John Bailye to the Company's Board of Directors, further bolstering its position as a leader in the pharmaceutical information services industry.

Mr. Bailye, 54, recently retired from his position as Chairman & CEO of Dendrite International after Dendrite was acquired by French information provider Cegedim. Under Mr. Bailye's leadership, Dendrite, a pharmaceutical sales force automation system company, grew to more than 3500 employees, acquired 23 companies and generated $450 million in global sales revenue to become the leading SFA tool in the pharmaceutical industry. Throughout his career, Mr. Bailye has served on a number of not-for-profit organizations, including the New Jersey Technology Council where he was co-Founder and Board Member. Currently, Mr. Bailye is also a director, advisor and investor in Solar Centre LLC, a General Partner of the Roxiticus Life Sciences Fund.

Kevin Leininger, Chief Executive Officer of IntegriChain commented, "We are thrilled to have John join our Board of Directors. John is a seasoned executive and leader who brings a wealth of experience and proven track record in building a strong information services company in the pharmaceutical industry."

"IntegriChain has an innovative approach to helping pharmaceutical companies take more advantage of their channel data for commercial applications such as forecasting, demand validation and product launch," said Mr. Bailye. "I am excited by the sizeable potential IntegriChain represents and I look forward to leveraging my experience to help the Company expand its possibilities even further."

About IntegriChain

IntegriChain, Inc. is an information services company which provides data collection, integration, enrichment, analysis and reporting of sales and inventory activity for the pharmaceutical industry. IntegriChain enables manufacturers to improve sales performance and increase patient safety by maximizing transparency and accountability in the supply chain. IntegriChain's Enriched Channel Sales(TM) and advanced analytics are transforming the role of channel data within key pharmaceutical application areas including new product launch, sales forecasting, and demand analysis.


'/>"/>
SOURCE IntegriChain, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trius Appoints Paul Truex to Board of Directors
2. Pelikan Technologies Appoints Denny Ware to Board of Directors
3. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
4. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
5. Nventa Appoints Gordon H. Busenbark to Board of Directors
6. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
7. Informed Medical Communications Appoints New Chief Financial Officer
8. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
9. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
10. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
11. VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):